AVERTO MEDICAL INC

Fremont, CA

OncologyGrant-only

Compare Sign in to watch

What changed

NIH R44 · $0.9M · Safety and Efficacy Trial of the ColoSeal ICD System for the Treatment of Rectal Cancer Patients

10mo agoGrant renewalSep 19, 2025Source filing (opens the source filing in a new tab)

Momentum

40no change

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

15,627 pre-ticker oncology companies at Grant-only

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R44 · $1.2M · non-dilutive
Sep 19, 2025
AVERTO MEDICAL INC · PI FONG, KENTON DODYAN · NIDDK · award ends Aug 31, 2027 · Safety and Efficacy Trial of the ColoSeal ICD System for the Treatment of Diverticular Disease Patients
NIH RePORTER · NIH RePORTER 11184789 (opens the source filing in a new tab)
Grant
R44 · $929k · non-dilutive
Sep 20, 2024
AVERTO MEDICAL INC · PI FONG, KENTON DODYAN · NCI · award ends Aug 31, 2026 · Safety and Efficacy Trial of the ColoSeal ICD System for the Treatment of Rectal Cancer Patients
NIH RePORTER · NIH RePORTER 11195700 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 77%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 1.00name similarity 100% · semantic similarity 91% · shared principal investigator / founder · same city · same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Investigators

The principal investigators named on the grants below. Each links to their federal grant record and every other company traced to their work.

Kenton Dodyan Fong

Event stream

Every scored event, newest first. This is what momentum is computed from.

NIH R44 · $0.9M · Safety and Efficacy Trial of the ColoSeal ICD System for the Treatment of Rectal Cancer Patients
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R44 · $1.2M · Safety and Efficacy Trial of the ColoSeal ICD System for the Treatment of Diverticular Disease Patients
10mo agoNew grantSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

R44 · $1.2M · non-dilutive

R44 · $929k · non-dilutive